Trust Company of Vermont’s Iovance Biotherapeutics IOVA Stock Holding History

Trust Company of Vermont’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,333	Closed	-$10K	–	957
2017 Q2	$10K	Hold	1,333	–	–	﹤0.01%	731
2017 Q1	$10K	Hold	1,333	–	–	﹤0.01%	708
2016 Q4	$9K	Buy	+1,333	New	+$9.17K	﹤0.01%	718
2016 Q2	–	Sell	-2,000	Closed	-$10K	–	849
2016 Q1	$10K	Buy	+2,000	New	+$10.9K	﹤0.01%	598

Other funds holding IOVA

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Trust Company of Vermont's IOVA Position: Q3 2017 in Review

Trust Company of Vermont sold out of Iovance Biotherapeutics (IOVA) in Q3 2017, closing a stake of 1,333 shares — an estimated $10K sold.

Trust Company of Vermont first reported a position in IOVA in Q1 2016 and held it in 4 quarters. The position peaked at $10K in Q2 2017. 85 funds tracked by Wall St. Rank hold IOVA as of Q3 2017.

Trust Company of Vermont reported no remaining Iovance Biotherapeutics position as of Q3 2017 after selling out during the quarter.
Trust Company of Vermont sold 1,333 Iovance Biotherapeutics shares in Q3 2017, an estimated $10K.
Trust Company of Vermont first reported a position in Iovance Biotherapeutics in Q1 2016 and held it in 4 quarters.
Trust Company of Vermont's Iovance Biotherapeutics position peaked at $10K in Q2 2017.
85 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2017.

Based on Trust Company of Vermont's 13F filing for Q3 2017, filed 24 Oct 2017.